Prescription and Off-Label Medication Approaches
Important Evidence Notice
No medication is currently FDA-approved specifically to cure Long COVID or chronic post-vaccination syndrome. Off-label prescribing is legal when clinically appropriate, but proposed mechanisms do not prove benefit. Treatment should use patient-specific goals, safety screening, monitoring, and a plan to stop ineffective therapy.
Ivermectin
Ivermectin is FDA-approved as an antiparasitic medication for specified infections. Its proposed Long COVID roles include anti-inflammatory signaling, modulation of NF-κB and cytokine pathways, interference with importin-mediated transport, and possible effects on viral proteins or host–virus interactions. Laboratory docking or cell-culture findings have also led to theories that ivermectin might interact with spike protein.
These mechanisms remain theoretical for Long COVID. Concentrations that inhibit SARS-CoV-2 in cell culture may not be safely achieved in people, large acute-COVID trials have not shown meaningful clinical benefit, and randomized prevention data did not show that early ivermectin reduced later Long COVID diagnoses. High-quality trials of ivermectin as treatment for established Long COVID are lacking. APNS should present it as an individualized investigational/off-label option, not as a proven spike-removal medication.
Safety
- Possible nausea, diarrhea, dizziness, rash, itching, fatigue, low blood pressure, and liver-test changes
- Rare serious neurologic or severe skin reactions
- Potential interactions with anticoagulants and other medications
- Veterinary ivermectin must never be used
- Repeated or higher-dose courses require particularly careful risk review and monitoring
Hydroxychloroquine
Hydroxychloroquine is an established prescription medication approved for selected forms of malaria, rheumatoid arthritis, and systemic lupus erythematosus. It is not FDA-approved for acute COVID-19, Long COVID, or chronic post-vaccination symptoms. Interest in Long COVID comes from its immunomodulatory effects in autoimmune disease and laboratory theories involving endosomal and lysosomal function.
How Hydroxychloroquine Is Theorized to Help
Hydroxychloroquine has been proposed as a potential treatment for some patients with Long COVID because of its effects on immune signaling and cellular processes. However, these proposed mechanisms remain largely theoretical, and clinical evidence demonstrating benefit for established Long COVID is currently limited.
| Proposed Mechanism | Possible Relevance to Long COVID | Current Limitation |
|---|---|---|
| Raises endosomal and lysosomal pH | Could alter endosomal processing, intracellular trafficking, antigen presentation, and selected cellular entry pathways. | A plausible cell-biologic mechanism does not establish clinical benefit in established Long COVID. |
| Toll-like receptor 7/9 modulation | May reduce innate immune signaling, type-I interferon pathways, and downstream cytokine activity. | Long COVID includes different immune phenotypes; broad modulation could be ineffective or mismatched. |
| Reduced antigen presentation and inflammatory signaling | Could theoretically help a subset with persistent autoimmune-like or inflammatory activity. | No validated test identifies a Long COVID subgroup proven to respond to hydroxychloroquine. |
| Effects on autophagy and lysosomal pathways | May alter cellular recycling and immune-cell behavior. | The direction and clinical importance of these effects in Long COVID are uncertain. |
| Proposed ACE2/spike-processing effects | Early laboratory hypotheses suggested altered receptor glycosylation or spike processing. | Human trials in acute COVID did not demonstrate meaningful clinical benefit; spike-binding or “detox” benefit is not established. |
| Zinc-ionophore theory | Some protocols proposed pairing hydroxychloroquine with zinc to increase intracellular zinc. | Direct zinc-ionophore activity and patient benefit remain disputed; high-dose zinc can cause toxicity and copper deficiency. |
Important: Hydroxychloroquine was studied extensively during acute COVID-19. Randomized trials did not demonstrate meaningful benefit in hospitalized patients, and outpatient evidence has not established reliable prevention of hospitalization or viral clearance. Evidence for treating established Long COVID is substantially weaker: publications mainly describe theoretical rationale and call for controlled trials rather than demonstrating effectiveness.
Safety and Monitoring
- QT prolongation, dangerous ventricular rhythm, cardiomyopathy, and interaction with other QT-prolonging medications—including concern when combined with azithromycin
- Irreversible retinal toxicity with cumulative exposure; baseline and ongoing ophthalmologic monitoring is required for longer-term use based on dose, duration, kidney function, and eye risk
- Severe hypoglycemia, even in patients without diabetes
- Serious skin reactions, blood-cell abnormalities, liver or kidney toxicity, muscle weakness, neuropathy, and neuropsychiatric reactions
- Additional caution with psoriasis, porphyria, G6PD deficiency, kidney disease, liver disease, electrolyte abnormalities, bradycardia, heart disease, or interacting medication
- Medication should be dispensed for human use and monitored with an individualized ECG, laboratory, and eye-care plan when clinically indicated
Evidence Position
Hydroxychloroquine may be discussed as a mechanistically interesting, investigational off-label option for a carefully selected patient, but it should not be described as a proven Long COVID antiviral, spike remover, or standard first-line treatment. Potential benefit must be weighed against cardiac and cumulative retinal risk.
Other Prescription Options Discussed
Several prescription medications have been proposed as potential treatments for Long COVID based on their effects on immune function, inflammation, metabolism, autonomic regulation, or symptom management. Most remain investigational for Long COVID, and treatment decisions should be individualized based on each patient’s clinical presentation, medical history, and current evidence.
| Medication | Proposed Long COVID Role | Evidence and Safety Position |
|---|---|---|
| Low-dose naltrexone (LDN) | May reduce microglial/TLR4 signaling, neuroinflammation, centralized discomfort, fatigue, and sleep disruption; may alter endorphin and immune signaling. | Promising small observational and pilot studies; randomized evidence remains limited. Must not be combined with opioids; see dedicated LDN page. |
| Metformin | AMPK activation, mTOR and mitochondrial effects, improved metabolic signaling, and possible antiviral/anti-inflammatory effects. | A randomized trial found lower Long COVID incidence when started during acute infection in adults with overweight/obesity. This does not prove treatment benefit for established Long COVID. |
| Fluvoxamine | Sigma-1 receptor signaling, possible cytokine and mast-cell effects, and treatment of coexisting anxiety/depression. | Acute-COVID and Long COVID evidence is mixed/limited. Has SSRI interactions, serotonin-syndrome risk, and discontinuation effects. |
| Prednisone/corticosteroids | Suppress inflammation in selected inflammatory, pulmonary, autoimmune, or organ-specific complications. | Not a general Long COVID cure. Prolonged empiric use can cause infection, glucose, bone, adrenal, mood, and other harms; may be dangerous with unrecognized Strongyloides. |
| Colchicine | Reduces inflammasome and neutrophil-mediated inflammation; used conventionally for pericarditis. | Use should be tied to an appropriate inflammatory indication; important kidney, liver, muscle, blood-cell, and interaction risks. |
| Famotidine / H1 antihistamines | May reduce histamine-mediated gastrointestinal, skin, respiratory, or mast-cell-like symptoms. | Symptom-directed use may be reasonable in selected patients; evidence for disease modification is limited. |
| Montelukast | Blocks leukotriene signaling; may reduce airway or eosinophilic inflammation. | Use for a defined respiratory/allergic pattern; carries an FDA boxed warning for serious neuropsychiatric events. |
| Nitazoxanide | Proposed host-directed antiviral, interferon, glycoprotein-processing, and anti-inflammatory effects. | Approved for certain protozoal infections, not Long COVID. Clinical evidence for established Long COVID is insufficient. |
| Hydroxychloroquine | Endosomal/lysosomal, TLR7/9, antigen-presentation, and immune-signaling theories. | No proven Long COVID efficacy; important QT/cardiomyopathy, irreversible retinal, hypoglycemia, severe skin, blood, and interaction risks. |
| POTS medications | Fludrocortisone, midodrine, clonidine, beta blockers, ivabradine, or pyridostigmine may target specific autonomic patterns. | Require phenotype-specific assessment; can worsen blood pressure, heart rate, electrolytes, or other symptoms if mismatched. |
| Antivirals for herpesvirus reactivation | Valacyclovir or related drugs may treat confirmed or strongly suspected herpesvirus disease. | EBV serology is complex; treatment should not be based on nonspecific fatigue alone. |
| Pentoxifylline, maraviroc, sildenafil, oxytocin, valproate, methylene blue | Proposed vascular, CCR5, perfusion, neuroimmune, mitochondrial, or symptom-specific effects. | Experimental for Long COVID; several carry major interaction, pregnancy, liver, blood-pressure, bleeding, or serotonin-related risks. |
| Anticoagulants/antiplatelets | Treat confirmed thrombosis or established cardiovascular indications. | “Microclot” protocols and triple therapy can cause major or fatal bleeding and should not be used without a conventional indication and specialist management. |
Adjunctive Treatments
Foundational and Lower-Risk Adjuncts
These supportive therapies are commonly discussed as part of a comprehensive Long COVID management plan. Most are intended to address nutritional status, oxidative stress, inflammation, or symptom management rather than treat the underlying cause of Long COVID. Evidence for many remains limited.
| Treatment | Proposed Rationale | Key Qualification |
|---|---|---|
| Vitamin C | Antioxidant and immune support. | Oral benefit for Long COVID unproven; high doses may cause GI effects or kidney stones. |
| Vitamin D3 / K2 | Immune and bone support; correct deficiency. | Test or review total intake; excess vitamin D can cause hypercalcemia. |
| B-complex vitamins | Cofactors for energy and neurologic function. | Useful for deficiency; excessive B6 can cause neuropathy. |
| Magnesium | Muscle, nerve, sleep, and autonomic support. | Diarrhea and kidney-related accumulation are possible. |
| Omega-3 | Anti-inflammatory lipid mediators. | Higher doses may increase bleeding risk and atrial fibrillation risk in some patients. |
| N-acetylcysteine (NAC) | Glutathione precursor; antioxidant and mucolytic effects. | Long COVID benefit unproven; interactions and GI effects possible. |
| Melatonin | Sleep support; proposed antioxidant and immune effects. | May cause sedation, vivid dreams, or drug interactions. |
| Probiotics | Microbiome support. | Effects are strain-specific; use caution in severe immune compromise. |
| Curcumin | Proposed anti-inflammatory and antioxidant effects. | Absorption varies; gallbladder, bleeding, and interaction concerns. |
| Quercetin / resveratrol | Proposed mast-cell, antioxidant, vascular, and autophagy effects. | Clinical evidence is limited; interactions and product variability matter. |
| Nigella sativa | Traditional anti-inflammatory and antioxidant use. | Long COVID evidence insufficient; may affect glucose, blood pressure, and clotting. |
| Sulforaphane | Nrf2 and antioxidant-response signaling. | Product composition varies; clinical benefit not established. |
Mast-Cell, Histamine, and Respiratory Adjuncts
Some patients experience symptoms that resemble mast-cell activation, histamine intolerance, or chronic airway inflammation. These therapies are generally considered symptom-directed rather than disease-modifying.
| Treatment | Proposed Role | Key Qualification |
|---|---|---|
| Loratadine or cetirizine | H1 blockade for itching, hives, flushing, nasal symptoms. | May help a symptom phenotype; sedation can occur. |
| Famotidine | H2 blockade for GI and histamine-related symptoms. | Kidney dosing and interactions should be reviewed. |
| Ketotifen | H1 antihistamine and mast-cell stabilizer. | Often compounded orally in the U.S.; sedation and dosing errors are possible. |
| Cromolyn | Mast-cell stabilization, especially GI symptoms. | Evidence in Long COVID is limited; administration is burdensome. |
| Luteolin | Flavonoid with proposed mast-cell effects. | Human Long COVID evidence is insufficient. |
| Montelukast | Leukotriene blockade for respiratory/allergic pattern. | Boxed warning for neuropsychiatric effects. |
| Diphenhydramine | Sedating H1 antihistamine. | Not preferred for routine chronic use due to sedation, falls, anticholinergic burden, and cognitive effects. |
Metabolic, Vascular, Neurologic, and Device Adjuncts
Additional therapies have been proposed to improve mitochondrial function, autonomic regulation, blood flow, or neurologic recovery. Most remain investigational, and their role in Long COVID has not been clearly established.
| Treatment | Proposed Role | Key Qualification |
|---|---|---|
| L-arginine | Nitric-oxide and endothelial support. | May lower blood pressure; avoid or review in certain cardiac, renal, or herpesvirus contexts. |
| Nattokinase | Fibrinolytic/antiplatelet theory. | Not proven to remove spike; may cause bleeding and interact with anticoagulants. |
| Bromelain | Proposed anti-inflammatory and fibrinolytic effects. | Bleeding, allergy, and interaction concerns; spike-cleavage claims are not clinically established. |
| Spermidine | Autophagy and neuroinflammation theory. | Clinical Long COVID benefit unknown; supplement amount is not equivalent to pure spermidine. |
| Photobiomodulation / near-infrared | Mitochondrial and inflammatory signaling theory. | Protocols vary; benefit and long-term safety are not established. |
| Vagus-nerve stimulation | Autonomic and anti-inflammatory signaling. | Investigational; device quality and protocols vary. |
| HBOT | Oxygenation, neuroplasticity, mitochondrial, and inflammatory effects. | Some small trials; costly, access-limited, and carries ear, lung, oxygen, and seizure risks. |
| Non-invasive brain stimulation | Cognition, depression, tinnitus, or neuroplasticity. | Specialist/device-based; evidence varies by symptom and protocol. |
| Low-magnitude mechanical stimulation | Conditioning and musculoskeletal support. | Avoid provoking PEM; evidence for Long COVID is limited. |
| Heat/cold exposure | Stress-response and mood theories. | May worsen POTS, dehydration, cardiovascular symptoms, or PEM. |
| Yoga, tai chi, relaxation, psychological support | Stress regulation, mobility, coping, and quality of life. | Should support—not imply symptoms are psychological; adapt to PEM and orthostatic intolerance. |
High-Risk or Highly Investigational Options From Source Slides
Several therapies have been proposed for Long COVID despite limited clinical evidence. These options generally carry greater uncertainty, higher risk, or should only be considered in research settings or under specialist supervision.
| Treatment | Proposed Role | Major Safety/Evidence Concern |
|---|---|---|
| Nicotine patches | Cholinergic-signaling theory. | Nicotine is addictive and can worsen heart rate, blood pressure, sleep, anxiety, and POTS; not established Long COVID therapy. |
| Methylene blue | Mitochondrial/redox and neurocognitive theory. | Potent MAO-A interaction at clinically relevant exposures; serotonin syndrome with serotonergic drugs, hemolysis in G6PD deficiency, pregnancy, and product-purity concerns. |
| Triple anticoagulation | Microthrombi theory. | Major or fatal bleeding risk; no routine validated Long COVID indication. |
| IV vitamin C | Antioxidant/endothelial theory. | Kidney injury, fluid/electrolyte issues, and hemolysis in G6PD deficiency; evidence insufficient. |
| IVIG or plasmapheresis | Autoimmune or antibody-removal theory. | Invasive, expensive, and risk-bearing; reserve for established indications or research/specialist care. |
| Maraviroc | CCR5 immune-signaling theory. | Liver, infection, interaction, and cost concerns; not established for Long COVID. |
| Intranasal oxytocin | Neuroimmune and symptom theory. | Compounded/investigational; cardiovascular, fluid, pregnancy, and dosing concerns. |
| Valproic acid | Antiviral or neuropsychiatric theory. | Major teratogenicity, liver, pancreatic, platelet, metabolic, and interaction risks; not a general Long COVID treatment. |
| Prednisone or other prolonged steroids | Inflammation suppression. | Infection, adrenal suppression, bone loss, diabetes, psychiatric effects, and Strongyloides hyperinfection risk. |
| Pentoxifylline / high-dose sildenafil | Microcirculation or perfusion theory. | Blood-pressure, bleeding, cardiac, vision, and interaction risks; specialist-guided investigational use only. |
Low-Dose Naltrexone (LDN) and Long COVID
What Is Low-Dose Naltrexone?
Naltrexone is FDA-approved at standard doses for alcohol and opioid use disorders. Low-dose naltrexone generally refers to much smaller daily doses—commonly about 0.5 to 4.5 mg—used off label for selected chronic pain, inflammatory, autoimmune, neurologic, and post-infectious conditions. LDN is often compounded because commercial tablets are much stronger.
How LDN Is Believed to Work
Low-dose naltrexone (LDN) has been proposed as a treatment for Long COVID because of its potential effects on immune regulation, neuroinflammation, pain processing, and endogenous endorphin signaling. While several mechanisms have been identified in laboratory and early clinical research, their relevance to Long COVID continues to be investigated.
| Proposed Mechanism | Possible Clinical Relevance |
|---|---|
| Transient opioid-receptor blockade | A brief blockade may produce rebound changes in endogenous endorphin signaling, potentially affecting pain, mood, immune regulation, and well-being. |
| TLR4 antagonism and microglial modulation | Laboratory and translational theories suggest reduced microglial activation and neuroinflammatory signaling, potentially relevant to brain fog, neuropathic discomfort, headache, and central sensitization. |
| Reduced NF-κB/cytokine signaling | May reduce selected inflammatory pathways without functioning as a broad immune suppressant. |
| TRPM3 and natural-killer-cell effects | Early laboratory work in Long COVID samples suggests LDN may restore altered ion-channel function; clinical importance remains under study. |
| Sleep and discomfort improvement | Better sleep and less discomfort may secondarily improve fatigue, cognition, activity tolerance, and quality of life. |
What the Evidence Shows
Small observational studies and pilot studies have reported improvements in fatigue, pain, brain fog, sleep, function, or quality of life in some patients. One pilot combined LDN with NAD+ patches, so the effect of LDN alone could not be determined. Published evidence remains limited by small samples, lack of placebo controls in much of the literature, variable definitions, and possible selection bias. Randomized trials are underway or emerging; LDN should be described as promising but unproven for Long COVID.
How It Is Commonly Introduced
Clinicians usually start low and increase gradually based on response and tolerability. The APNS source job aid describes 1.5 mg daily for four weeks, then 3 mg daily for four weeks, then 4.5 mg daily. Some sensitive patients require a lower starting dose or slower titration. Benefits, if they occur, may take several weeks or months.
Possible Side Effects
- Vivid dreams or sleep disturbance
- Headache, dizziness, anxiety, or restlessness
- Nausea, reduced appetite, abdominal symptoms, or fatigue
- Temporary flu-like feelings
- Rare liver-test abnormalities or allergic reaction
Who Should Not Use LDN Without Specialized Review?
- Anyone currently using opioid medication, opioid-containing cough or diarrhea products, illicit opioids, or receiving opioid-use-disorder medication
- Anyone who may need opioid analgesia for an upcoming procedure
- People with acute hepatitis or severe liver impairment
- Pregnant or breastfeeding patients unless specifically evaluated
- Patients with significant kidney disease, complex psychiatric illness, or multiple interacting medications
- Anyone with possible physiologic opioid dependence, because naltrexone can precipitate severe withdrawal
Surgery and Pain Treatment
Because naltrexone blocks opioid receptors, it can make opioid pain medication ineffective and complicate emergency or procedural pain control. Patients must tell every prescriber, surgeon, dentist, and emergency clinician that they take LDN. The timing for stopping and restarting must be individualized; a universal 48-hour rule is not sufficient for every procedure or patient.
How APNS Can Evaluate Response
- Select two to four target symptoms before starting
- Record baseline fatigue, PEM, sleep, discomfort, cognition, and function
- Increase gradually only when tolerated
- Reassess after an adequate trial
- Stop or adjust for significant adverse effects
- Discontinue if there is no meaningful benefit after an appropriate trial
- Do not combine with opioid medication
Ready to take control of Long COVID?
Whether you’re experiencing persistent symptoms after COVID-19 or looking for additional support after months or years of ongoing illness, APNS is here to help. Our providers will work with you to develop a personalized evaluation and treatment plan based on your symptoms, medical history, and individual needs, with the goal of improving function, quality of life, and long-term health.